PrimeRFP
PrimeRFP SCOUT · Federal Contract Recompete Brief

15F06726F0000234GSK vaccines TERMS and conditions REMAIN — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 15F06722A0000187. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: Unrestricted. Recompete timing centers on the Dec 31, 2026 PoP end — agencies typically plan 12–18 months ahead.

Division 1200
Awarding office
Glaxosmithkline LLC
Recipient
Dec 31, 2026
PoP end
$33K
Obligated
$113K
Potential
325412
NAICS
6515
PSC
Unrestricted
Set-aside
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Unrestricted
Contract number15F06726F0000234
Also listed as15F06722A0000187-15F06726F0000234
AgencyDivision 1200
Awarding officeDivision 1200
Awarding agencyDepartment of Justice (DOJ)
Funding agencyDepartment of Justice (DOJ)
IncumbentGlaxosmithkline LLC
CAGE667E9
UEIFRHTPHMZMX47
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6515
Parent IDIQ / IDV15F06722A0000187
Place of performanceDURHAM NC
Pricing typeFirm Fixed Price
Extent competedCompeted Under SAP
PoP startFeb 27, 2026
PoP end (current)Dec 31, 2026
Obligated$33K
Current value$113K
Potential value$113K

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187 is a federal Unrestricted award for Division 1200 held by Glaxosmithkline LLC. Estimated value $113K ($33K obligated). Current period of performance ends Dec 31, 2026. Last award drew 1 bidder. Place of performance: DURHAM NC.

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187

Recompete timing

Public
● Expiring in 91 days

Current PoP ends Dec 31, 2026 (91 days remaining). Agencies typically plan 12–18 months ahead — at 3.0 months out, that window is already open. The buying decision is likely already in motion.

Bonuses end Sept 30

Want the durability read on 15F06726F0000234? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies
Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%
Open full company profile →

Related awards

Same parent · incumbent
75A50126F61020
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…
$493K
Oct 29, 2026
15F06724F0001366
GSK TRAVEL VACCINES
$115K
Dec 31, 2026
75A50124F61014
THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …
$18.4M
Feb 21, 2027
75A50124F61013
THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) …
$15.4M
Feb 21, 2027
75A50124F61010
THE PURPOSE OF THIS TASK ORDER IS TO PROCURE STORAGE AND STABILITY FOR ANTIGENS AND ADJUVA…
$40.9M
May 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 15F06726F0000234?

15F06726F0000234 (GSK vaccines TERMS and conditions REMAIN) is a Division 1200 award with a potential value of $113K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 15F06726F0000234?

Division 1200 awarded 15F06726F0000234 to Glaxosmithkline LLC (potential $113K).

Who is the incumbent on 15F06726F0000234?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2026.

When does Glaxosmithkline LLC’s 15F06726F0000234 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 15F06726F0000234? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/15F06726F0000234